Full Press Release Details
Pharmaceuticals Announces Topline Results from determine Phase 3 Study of
Lenabasum for Treatment of Dermatomyositis
MA, June 24, 2021 (GLOBE NEWSWIRE) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"),
an immunology company developing innovative medicines that target inflammation, fibrosis, metabolism and immuno-oncology, today announced
topline results from the Phase 3 DETERMINE study of lenabasum in adults with the rare, heterogeneous, autoimmune
disease dermatomyositis.
study did not meet its primary endpoint of Total Improvement Score (TIS) at Week 28. Higher TIS values indicate greater overall improvement.
At Week 28, the lenabasum 20 mg twice daily group achieved a mean TIS of 28.3 versus the control group mean TIS of 26.7, p = 0.1965.
All subjects, including the control group, received standard background treatments, with 89% of dosed subjects receiving 1 immunosuppressive
or immunomodulating therapy. Additional pre-specified analyses of the overall effect on TIS of lenabasum 20 mg twice daily versus control
group through Week 52 showed a trend of beneficial effect of lenabasum, nominal p = 0.0795.
patients have characteristic muscle weakness and inflammatory skin involvement. This study enrolled subjects with the two major types
of dermatomyositis: classic dermatomyositis with both muscle weakness and skin involvement and dermatomyositis with no significant muscle
weakness but with skin involvement. Improvement in muscle weakness is heavily weighted in the TIS score. In the overall study, higher
TIS scores were seen in those subjects who had muscle weakness (Manual Muscle Test-8 muscle group score < 142) and were treated with
lenabasum 20 mg twice daily versus the control group, nominal p = 0.0302. Conversely, the Cutaneous Dermatomyositis Activity and Severity
Index (CDASI) activity score, a secondary endpoint in this study, is a validated outcome that was designed to assess inflammatory skin
involvement in dermatomyositis. In the overall study, greater improvement (reduction) in CDASI activity scores was seen in subjects with
skin involvement but no muscle weakness who were treated lenabasum 20 mg twice daily versus the control group, nominal p = 0.0166. This
is a similar patient population and the same endpoint as was tested in Corbus' previously completed Phase 2 study (ClinicalTrials.gov
Identifier: NCT02466243).
of lenabasum on lung function was a secondary endpoint in this study, and no statistically significant difference was seen at Week 28
in the lenabasum 20 mg twice daily group versus control group. In the overall study, other pre-specified analyses showed that subjects
on stable immunosuppressive therapies (> 1 year treatment duration) had an improvement in forced vital capacity compared to the control
group, nominal p = 0.0591.
results for the lenabasum 5 mg twice daily group were generally similar to those for the control group.
data showed 86.5% of lenabasum-treated subjects and 85.9% of control subjects had treatment-emergent adverse events (AEs), 11.5% of lenabasum-treated
subjects and 5.6% of control subjects had serious AEs, and no lenabasum-treated subject and 1 control subject discontinued study drug
because of an AE related to study drug. Adverse events that occurred in 10% lenabasum-treated subjects and also in 5% more
lenabasum-treated subjects than control subjects were diarrhea (12.5% versus 7.0%), dizziness (10.6% versus 4.2%), and nausea (10.6%
versus 4.2%). There were fewer AEs of dermatomyositis worsening in the lenabasum 20 mg twice daily group than the control group (27 versus
from this study will be presented at an upcoming medical conference.
are disappointed that the trial did not meet the primary endpoint of TIS at Week 28," said Barbara White, M.D., Chief Medical Officer
and Head of Research at Corbus. "Nonetheless, we are encouraged by the results when the outcome is matched to the subtype of dermatomyositis
in the study. We believe we see clinical activity of lenabasum 20 mg administered twice daily compared to the control group just receiving
standard background treatments, with higher TIS scores in classic dermatomyositis subjects with muscle weakness and skin involvement
and greater reduction in CDASI activity score in subjects with active skin disease but normal muscle strength. We thank the participants,
investigators and clinical site study staff, and the patient advocacy community for their support of this study."
Werth, M.D., Professor of Dermatology and Medicine, University of Pennsylvania Perelman School of Medicine and Chief of Dermatology,
Corporal Michael J. Crescenz VAMC, said, "I'm pleased by the improvement in CDASI activity scores seen in dermatomyositis
patients with minimal active muscle disease in this study. It is difficult to conduct a large stand-alone study in just this small subtype
of patients. In such a complex disease, seeing this subtype with refractory skin disease respond so well in this and the Phase 2 study
is promising. These patients frequently have widespread disfiguring, symptomatic and refractory skin manifestations, and there is a need
for new treatments, especially those that are not immunosuppressive. Our skin biomarker data from Phase 2 show reductions in inflammatory
cytokines and T cells with lenabasum treatment compared to placebo, supporting improvement in skin disease in these patients. The improvement
in TIS in subjects with muscle weakness is also interesting. It is clear to me that we have to look at the organs that are involved and
use outcomes that correspond to those organs to detect change in dermatomyositis."
Cohen, Ph.D., Chief Executive Officer, commented, "We look forward to discussing the data from the Phase 2 and Phase 3 dermatomyositis
studies with regulatory authorities and seeking their input on next steps. With our strong cash position, we have the resources to both
advance our now diversified pipeline while also planning next steps for lenabasum."
Phase 3 Study Design
Phase 3 trial evaluated the safety and efficacy of lenabasum in adults with active classic or amyopathic dermatomyositis who were receiving
standard treatments. This international study dosed 175 subjects who were randomized 2:1:2 to receive lenabasum 20 mg twice per day (n
= 69), lenabasum 5 mg twice per day (n = 35), or placebo twice per day (n = 71), all added to background treatments. The primary efficacy
endpoint was the composite American College of Rheumatology/European League Against Rheumatism 2016 Total Improvement Score at Week 28,
comparing lenabasum 20 mg twice daily versus placebo. Change in CDASI activity score and forced vital capacity were among secondary efficacy
endpoints. As previously disclosed, in this study of up to one year duration, the timing of the primary efficacy endpoint was changed
from Week 52 to Week 28.
is a novel, oral, small molecule designed to provide an alternative to immunosuppressive treatments for inflammatory or fibrotic diseases.
Lenabasum binds to and activates the cannabinoid receptor type 2 (CB2), which is preferentially expressed on activated immune cells,
to resolve inflammation and limit fibrosis. Data from animal models and human clinical studies suggest that lenabasum can reduce expression
of genes and proteins involved in inflammation and fibrosis. In clinical testing to date, lenabasum has acceptable safety and tolerability
a form of idiopathic inflammatory myositis, is a chronic, rare, inflammatory, clinically heterogenous, and sometimes life-threatening
autoimmune disease affecting approximately 80,000 people in North America, EU and Japan.1 The signs and symptoms of dermatomyositis
reflect multi-organ involvement, which includes distinctive skin rashes usually accompanied by proximal muscle weakness, and can also
include pulmonary, cardiac, gastrointestinal, and joint involvement.2 Patients with dermatomyositis can have recurrent disease
flares or chronic progressive disease activity, with increased mortality.3,4 The current mainstay of treatments include FDA-approved
systemic glucocorticoids and off-label use of glucocorticoid-sparing immunosuppressive or immunomodulating agents.5,6 There
is significant unmet need for new treatments to achieve disease control in dermatomyositis because of limited efficacy or toxicity of
immunosuppressive agents or refractory disease.7,8
is committed to connecting innovation to our purpose of improving lives by developing new medicines that target inflammation, fibrosis,
metabolism and immuno-oncology, by building upon our underlying expertise in immunology. Corbus' current pipeline includes small
molecules that activate or inhibit the endocannabinoid system and anti-integrin monoclonal antibodies that block activation of TGF .
Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on
Twitter, LinkedIn and Facebook.
press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the
Company's restructuring, trial results, product development, clinical and regulatory timelines, market opportunity, competitive
position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that
are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about
the industry and markets in which we operate and management's current beliefs and assumptions.
statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate,"
"intend," "plan," "believe," "estimate," "potential," "predict,"
"project," "should," "would" and similar expressions and the negatives of those terms. These statements
relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors, including
the potential impact of the recent COVID-19 pandemic and the potential impact of sustained social distancing efforts, on our operations,
clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from
any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set
forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue
reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation
to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Pharmaceuticals Contacts:
Jenkins, Senior Director, Investor Relations and Corporate Communications
Smith, Director, Investor Relations and Corporate Communications